Jerzy Tujakowski
Overview
Explore the profile of Jerzy Tujakowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jarzabek T, Rucinska M, Rogowski W, Lewandowska M, Tujakowski J, Habib M, et al.
Mol Diagn Ther
. 2015 Feb;
19(2):79-89.
PMID: 25721848
Background And Objective: Epidermal growth factor receptor (EGFR) inhibitors are not equally effective in all cancer patients. One potential clinical factor that could help in selecting patients who may benefit...
2.
Slupski M, Wlodarczyk Z, Jasinski M, Masztalerz M, Tujakowski J
Can J Surg
. 2009 Dec;
52(6):E241-4.
PMID: 20011158
Background: The optimal strategy for the treatment of synchronous colorectal liver metastases has not been established yet. In this study, we present the outcomes and survival rates of the patients...
3.
Wojtukiewicz M, Sierko E, Rybaltowski M, Filipczyk-Cisarz E, Staroslawska E, Tujakowski J, et al.
Int J Hematol
. 2009 Apr;
89(3):276-284.
PMID: 19343481
The purpose of the retrospective study in cancer patients in Poland was to analyze the frequency of anemia and methods of its treatment. An attempt was also made to evaluate...
4.
Siomek A, Tujakowski J, Gackowski D, Rozalski R, Foksinski M, Dziaman T, et al.
Int J Cancer
. 2006 Jun;
119(9):2228-30.
PMID: 16804900
There is growing evidence suggesting that cytotoxic activity of cisplatin is closely associated with increased generation of reactive oxygen species (ROS). Therefore, this study was undertaken to examine oxidative DNA...
5.
Twelves C, Wong A, Nowacki M, Abt M, Burris 3rd H, Carrato A, et al.
N Engl J Med
. 2005 Jul;
352(26):2696-704.
PMID: 15987918
Background: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment...